<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615211</url>
  </required_header>
  <id_info>
    <org_study_id>W300TL</org_study_id>
    <nct_id>NCT01615211</nct_id>
  </id_info>
  <brief_title>Randomized Study of Letrozole and Trilostane for Medical Abortion</brief_title>
  <official_title>A Randomized Pilot Study of Two New Drug Combinations Fot the Termination fo Early Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristina Gemzell Danielsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In menstruation an effective shedding of the endometrial lining occurs. Both progesterone and
      estrogen levels fall sharply at this time. During medical abortion the endometrial shedding
      is sometimes ineffective causing an incomplete abortion which may cause prolonged bleeding or
      require surgical intervention. In medical abortion a progesterone antagonist is used as
      treatment but the estrogen levels are not targeted. The investigators wish to explore whether
      addition of letrozole or trilostane which target estrogen levels can lead to a more effective
      shedding of the endometrial lining.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No access to study drug Trilostan. Company closed down
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Evaluation of complete abortion by clinical judgement and ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>1 week, 2 weeks and 4 weeks</time_frame>
    <description>questionnaire. Preferred future method of medical abortion.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Medical Abortion, Complete or Unspecified, Without Complication</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trilostane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets</description>
    <arm_group_label>Letrozole</arm_group_label>
    <other_name>Brand name Femar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trilostane</intervention_name>
    <description>Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice</description>
    <arm_group_label>trilostane</arm_group_label>
    <other_name>Brand name Modrenal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women aged 18-45 without any contraindication for treatment of any of the
             drugs involved in teh study

        Exclusion Criteria:

          -  Any ongoing medication or medical condition smoking &gt;20 cigarettes per day BMI &gt;30
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gemzell Danielsson, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Kopp Kallner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17177</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kristina Gemzell Danielsson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Abortion</keyword>
  <keyword>medical abortion</keyword>
  <keyword>termination of pregnancy</keyword>
  <keyword>Mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>letrozole</keyword>
  <keyword>trilostane</keyword>
  <keyword>femara</keyword>
  <keyword>Modrenal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Trilostane</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
    <mesh_term>Dihydrotestosterone</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

